We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.49
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.98 (16.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 6.49
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Plantic Technologies, Acal, Anglesey

Thu, 29th Jul 2010 12:51

Shares in Plantic Technologies soared more than 50% after the biodegradeable plastics outfit agreed an 8p per share offer from a company controlled by Gordon Merchant, one of its directors. Acal, which provides technology products and services across Europe and South Africa, said underlying sales for the first quarter increased by around 20% year on year and orders, a measure of current demand, increasing by 29%.Anglesey Mining is up on news that its 41% owned associate company Labrador Iron Mines received approvals to commence construction of its mining facilities from the government of Newfoundland and Labrador.Shares in bakery ingredients maker Real Good Food fell back after it reported good trading at its businesses, though the sugar business was impacted by lower prices.Shares in office space provider Serviced Office climbed after it reported a widening in losses but said that recent changes including opening new buildings and developing a sales team should augur a return to profit.In the half year to June 30, pre-tax losses widened to £272,000 from £207,000 over the same period the previous year, even as revenues jumped to £4.6m from £3.3m.'The changes we have made, coupled with the result to date, indicate a future return to profitability and I have great confidence in continued improvement going forwards,' said chairman Michael Kingshott.Respiratory drug discovery and development company Synairgen posted a pre-tax loss of £2.9m in the year to June 30, more than the £2.8m deficit the previous year as it continued its R&D programme.
More News
22 Jul 2015 10:44

AstraZeneca starts next phase of testing on Synairgen asthma drug

(ShareCast News) - Synairgen announced AstraZeneca started another phase of testing on its asthma drug. AIM listed Synairgen said AstraZeneca begun its Phase IIa trial of the drug AZD9412 and expected results in early 2017. AstraZeneca would test 220 asthma patients whose conditions were exacerbate

Read more
22 Jul 2015 07:00

Synairgen Says AstraZeneca Begins Phase IIa Trial In Severe Asthma

Read more
22 Jun 2015 07:28

LONDON BRIEFING: Stocks Surge On Optimism For Greek Debt Deal

Read more
22 Jun 2015 05:13

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 15:14

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 05:21

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 15:06

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 05:27

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 14:56

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 15:03

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
15 Jun 2015 14:52

AGM, EGM Calendar - Week Ahead

Read more
3 Mar 2015 08:38

Synairgen Swings To 2014 Pretax Profit On AstraZeneca Licence Deal

Read more
21 Oct 2014 08:50

Tuesday broker round-up UPDATE

African Barrick Gold: JP Morgan cuts target price from 340p to 300p and stays with its overweight rating. Anglo American: JP Morgan raises target price from 1240p to 1310p, while leaving its underweight rating unchanged. Investec increases target price from 1573p to 1603p and stays with its buy reco

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.